|  | | 2952 | Abatacept(Orencia®)forInjectionforIntravenousUseMA08.028f | Pharmacy (08) | MA08.028f | MA08.028 | c8843da7-d3aa-47c9-92f6-605aa648b496 | Abatacept (Orencia®) for Injection for Intravenous Use | Abatacept (Orencia®) for Injection for Intravenous Use | {"2953": {"Id":2953,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":5705,"PolicyAttachmentPageName":"8d160c91-5b61-4e47-8d51-aeb4edf972df"},} | |
|  | | 2507 | AbortionMA11.010a | Surgery (11) | MA11.010a | MA11.010 | 5e7d70e9-cd59-4945-8fd8-e5552ecdbe7f | Abortion | Abortion | | |
|  | | 3023 | AcupunctureMA12.004c | Miscellaneous (12) | MA12.004c | MA12.004 | 8d122c3d-9edc-4add-81d3-b1c65ff2de78 | Acupuncture | Acupuncture | {"3024": {"Id":3024,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":5772,"PolicyAttachmentPageName":"c5403db5-1625-4eb7-b584-629290d58152"},} | |
|  | | 2689 | AcuteCareFacilityInpatientTransfersMA12.003a | Miscellaneous (12) | MA12.003a | MA12.003 | 534525a5-76f0-4bce-9bd9-d6dcff647b59 | Acute Care Facility Inpatient Transfers | Acute Care Facility Inpatient Transfers | | |
|  | | 3182 | Ado-TrastuzumabEmtansine(Kadcyla®)MA08.066e | Pharmacy (08) | MA08.066e | MA08.066 | 5f25974a-991e-490a-8a33-8d6a3fa71a7d | Ado-Trastuzumab Emtansine (Kadcyla®) | Ado-Trastuzumab Emtansine (Kadcyla®) | {"3183": {"Id":3183,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5901,"PolicyAttachmentPageName":"a5920afd-efb8-4cba-a212-104df2b8fffa"},} | |
|  | | 3434 | Agalsidasebeta(Fabrazyme®)MA08.033c | Pharmacy (08) | MA08.033c | MA08.033 | 72b0047c-3b34-4685-ad68-a0a2b71933b1 | Agalsidase beta (Fabrazyme®) | Agalsidase beta (Fabrazyme®) | | |
|  | | 2758 | AirAmbulanceServicesMA12.007a | Miscellaneous (12) | MA12.007a | MA12.007 | 8e39da98-8d07-4c8a-bef5-02fa5b6a5006 | Air Ambulance Services | Air Ambulance Services | | |
|  | | 2768 | Alemtuzumab(Lemtrada®)MA08.015d | Pharmacy (08) | MA08.015d | MA08.015 | 90901d4f-1362-4821-9241-f9bed7689f50 | Alemtuzumab (Lemtrada®) | Alemtuzumab (Lemtrada®) | | |
|  | | 3525 | Alglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®)MA08.036f | Pharmacy (08) | MA08.036f | MA08.036 | e5598147-140e-442f-b181-fb610293bd70 | Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ) | Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ) | | |
|  | | 2592 | AllergyImmunotherapyMA07.055d | Medicine (07) | MA07.055d | MA07.055 | 719b74d6-420c-4235-bd9c-701076317da1 | Allergy Immunotherapy | Allergy Immunotherapy | | |
|  | | 3146 | Alpha1-AntitrypsinTherapy(e.g.,Prolastin-C,AralastNP,Glassia,Zemaira)MA08.050b | Pharmacy (08) | MA08.050b | MA08.050 | 1e16c2b1-95c7-45d6-9c02-05c6823a4816 | Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C, Aralast NP, Glassia, Zemaira) | Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C, Aralast NP, Glassia, Zemaira) | | |
|  | | 3460 | AlwaysBundledProcedureCodesMA00.026n | Administrative (00) | MA00.026n | MA00.026 | c308d403-fa13-4dbf-9ff8-232d4a5cdeeb | Always Bundled Procedure Codes | Always Bundled Procedure Codes | {"3461": {"Id":3461,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":6313,"PolicyAttachmentPageName":"4c929de9-66d8-4c7e-bfc6-0aa7b60e83f5"},"3462": {"Id":3462,"MPAttachmentLetter":"A","Title":"Always Bundled Procedures (MPFSD Indicator B)","MPPolicyAttachmentInternalSourceId":6314,"PolicyAttachmentPageName":"bfe56c96-a3ed-4ee1-8564-21218c6b70eb"},"3463": {"Id":3463,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":6315,"PolicyAttachmentPageName":"04778e62-489d-47c3-93ff-d4429e47d70e"},} | |
|  | | 2460 | AmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)DevicesMA07.005c | Medicine (07) | MA07.005c | MA07.005 | 301346f4-5db6-4773-ade7-a8c8bddfe5fe | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | | |
|  | | 3252 | AmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)MonitoringMA07.026h | Medicine (07) | MA07.026h | MA07.026 | 461ba619-2fe9-42bd-8492-8bed8ec39944 | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | | |
|  | | 3443 | AnesthesiaServicesforEpidural,ParavertebralFacetandSacroiliacJointInjectionsforSpinalJointManagementMA01.008 | Anesthesia (01) | MA01.008 | MA01.008 | 3e940a7a-241b-4ffe-bc71-efda073f90f4 | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | {} | |
|  | | 3431 | Anifrolumab-fnia(Saphnelo™)MA08.140b | Pharmacy (08) | MA08.140b | MA08.140 | c8972418-fb77-4496-a360-272ec63eff5b | Anifrolumab-fnia (Saphnelo™) | Anifrolumab-fnia (Saphnelo™) | | |
|  | | 2830 | Ankle-Foot/Knee-Ankle-FootOrthosesMA05.010g | DME (05) | MA05.010g | MA05.010 | 4381bbfc-9be4-4c1d-be48-104f3d74cddf | Ankle-Foot/Knee-Ankle-Foot Orthoses | Ankle-Foot/Knee-Ankle-Foot Orthoses | {"2831": {"Id":2831,"MPAttachmentLetter":"A","Title":"HCPCS CODES FOR ANKLE-FOOT/ KNEE-ANKLE FOOT ORTHOSIS","MPPolicyAttachmentInternalSourceId":5438,"PolicyAttachmentPageName":"abe26858-dc87-4040-a463-5b67d4bafc0c"},} | |
|  | | 3503 | AnorectalManometry,Electromyography(EMG)ofAnorectalorUrethralSphincters;BiofeedbackTrainingforPerinealMusclesandAnorectalorUrethralSphinctersMA07.018b | Medicine (07) | MA07.018b | MA07.018 | 6784e81c-0d85-46ea-8570-0305b1408593 | Anorectal Manometry, Electromyography (EMG) of Anorectal or Urethral Sphincters; Biofeedback Training for Perineal Muscles and Anorectal or Urethral Sphincters | Anorectal Manometry, Electromyography (EMG) of Anorectal or Urethral Sphincters; Biofeedback Training for Perineal Muscles and Anorectal or Urethral Sphincters | | |
|  | | 2179 | ApheresisTherapyMA06.001e | Pathology and Laboratory (06) | MA06.001e | MA06.001 | a8e854f7-94e7-4833-a02c-b7fb4214ff25 | Apheresis Therapy | Apheresis Therapy | | |
|  | | 3515 | ApplicationandRemovalofTattoosMA11.072 | Surgery (11) | MA11.072 | MA11.072 | 5e7b3431-7254-494b-91b5-f3edb685eb24 | Application and Removal of Tattoos | Application and Removal of Tattoos | | |
|  | | 2881 | Aprepitant(Cinvanti™),FosaprepitantDimeglumine(Emend®),Granisetron(Sustol®),andRolapitant(Varubi®)MA08.091c | Pharmacy (08) | MA08.091c | MA08.091 | 2db5cb4d-4bc2-4894-b0b9-ff440fda15da | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | {"2882": {"Id":2882,"MPAttachmentLetter":"A","Title":"Risk of Emesis Without Prophylaxis: Intravenous and Oral Antineoplastic Agents","MPPolicyAttachmentInternalSourceId":5661,"PolicyAttachmentPageName":"f1fed1fc-a936-48d8-8d28-4ada8844ac1e"},} | |
|  | | 3287 | AqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucomaMA11.105h | Surgery (11) | MA11.105h | MA11.105 | 8d7083aa-d91b-42cd-a9d2-2436df8015fd | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | {"3288": {"Id":3288,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":6071,"PolicyAttachmentPageName":"88201f50-d557-44c7-ad4b-4e27db15c051"},} | |
|  | | 3056 | ArtificialIntervertebralLumbarDiscInsertionMA11.114 | Surgery (11) | MA11.114 | MA11.114 | db5c146e-b18a-4e6a-931c-33f744b37c96 | Artificial Intervertebral Lumbar Disc Insertion | Artificial Intervertebral Lumbar Disc Insertion | | |
|  | | 3310 | Asparaginaseerwiniachrysanthemi(Erwinaze®),asparaginaseerwiniachrysanthemi(recombinant)-rywn(Rylaze™)MA08.085e | Pharmacy (08) | MA08.085e | MA08.085 | cc37bdfd-4bcc-491d-8a01-26bac662db26 | Asparaginase erwinia chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) | Asparaginase erwinia chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) | | |
|  | | 3391 | Atezolizumab(Tecentriq®)MA08.127b | Pharmacy (08) | MA08.127b | MA08.127 | cde82c5a-0a80-4bfb-9c2f-a6bec18e4a07 | Atezolizumab (Tecentriq®) | Atezolizumab (Tecentriq®) | {"3392": {"Id":3392,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6122,"PolicyAttachmentPageName":"1f3a7a81-eda4-44e7-a9a5-f6286558df75"},} | |
|  | | 2904 | AutomaticExternalCardioverterDefibrillators(WearableandNonwearable)MA05.005d | DME (05) | MA05.005d | MA05.005 | 5597ec50-4ed6-47ed-a1f6-ec70e871649a | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | {"2905": {"Id":2905,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":5696,"PolicyAttachmentPageName":"ed6d8443-570b-4f46-8682-17aab3910728"},"2906": {"Id":2906,"MPAttachmentLetter":"A","Title":"ICD-10 codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":5697,"PolicyAttachmentPageName":"8dd85c76-d455-4bef-bc25-e1327b353d7d"},} | |
|  | | 3273 | AutonomicNervousSystemTestingMA07.027e | Medicine (07) | MA07.027e | MA07.027 | 88c7b6d9-8d91-43d3-abfa-cde96d8d500f | Autonomic Nervous System Testing | Autonomic Nervous System Testing | | |
|  | | 3304 | Avelumab(Bavencio®)MA08.122a | Pharmacy (08) | MA08.122a | MA08.122 | c806ce2a-769d-48f7-a30c-2cfeb52836f0 | Avelumab (Bavencio®) | Avelumab (Bavencio®) | {"3305": {"Id":3305,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6027,"PolicyAttachmentPageName":"990f7252-595d-48ad-bbee-e9b41d917538"},} | |
|  | | 3148 | BalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitisMA11.100e | Surgery (11) | MA11.100e | MA11.100 | 96362b3e-c9dd-4016-ba9b-848e1daa84c4 | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis | Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis | | |
|  | | 3532 | belantamabmafodotin-blmf(Blenrep)MA08.119b | Pharmacy (08) | MA08.119b | MA08.119 | cf4b9338-44d8-4be3-b8af-86f6920be908 | belantamab mafodotin-blmf (Blenrep) | belantamab mafodotin-blmf (Blenrep) | | |
|  | | 3381 | Belimumab(Benlysta®)forIntravenousUseMA08.057c | Pharmacy (08) | MA08.057c | MA08.057 | 16ac27d9-275a-45ac-9a62-6ed58a355d9f | Belimumab (Benlysta®) for Intravenous Use | Belimumab (Benlysta®) for Intravenous Use | | |
|  | | 3389 | Bevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUseMA08.072i | Pharmacy (08) | MA08.072i | MA08.072 | 41ad24ae-0026-45ae-8fc8-3b701c04bd70 | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | {"3390": {"Id":3390,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":6053,"PolicyAttachmentPageName":"bb080a18-a681-45b6-8402-40e3647cb380"},} | |
|  | | 3321 | BillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampusMA00.037k | Administrative (00) | MA00.037k | MA00.037 | fa386a65-d740-4764-878d-b0c03ccee966 | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus | {"3322": {"Id":3322,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus - CPT/HCPCS Codes","MPPolicyAttachmentInternalSourceId":6120,"PolicyAttachmentPageName":"59902f83-9042-435b-95fb-a2fc79a83db1"},} | |
|  | | 3055 | BiofeedbackTherapyMA07.010a | Medicine (07) | MA07.010a | MA07.010 | 828edbc7-c517-4223-89ea-9740a68d2964 | Biofeedback Therapy | Biofeedback Therapy | | |
|  | | 2745 | BioimpedancefortheDetectionofLymphedemaMA07.052 | Medicine (07) | MA07.052 | MA07.052 | c1e6aafa-0100-443d-9127-3883ac43bb26 | Bioimpedance for the Detection of Lymphedema | Bioimpedance for the Detection of Lymphedema | | |
|  | | 3139 | Blepharoplasty,RepairofBlepharoptosis,RepairofBrowPtosis,andCanthoplasty/CanthopexyMA11.047d | Surgery (11) | MA11.047d | MA11.047 | 2d373d81-6a26-4c58-ac15-91a4a9852ce4 | Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy | Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy | {"3140": {"Id":3140,"MPAttachmentLetter":"A","Title":"ICD-10 Coding","MPPolicyAttachmentInternalSourceId":5957,"PolicyAttachmentPageName":"ded3956f-21da-4869-96e4-ea6aa23ba7a1"},} | |
|  | | 2707 | Blinatumomab(Blincyto®)MA08.058d | Pharmacy (08) | MA08.058d | MA08.058 | 2ee48daf-823a-407f-9a59-ee7b1644b7e5 | Blinatumomab (Blincyto®) | Blinatumomab (Blincyto®) | | |
|  | | 3331 | Bone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAidsMA11.049d | Surgery (11) | MA11.049d | MA11.049 | 436fa6c6-3279-4818-bdb6-e96b99bf1a19 | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | | |
|  | | 3446 | Bortezomib(BortezomibforInjection,Velcade®)MA08.037h | Pharmacy (08) | MA08.037h | MA08.037 | 9a2434d8-c271-4dea-a383-55f0c9886c7f | Bortezomib (Bortezomib for Injection, Velcade®) | Bortezomib (Bortezomib for Injection, Velcade®) | {"3447": {"Id":3447,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6197,"PolicyAttachmentPageName":"f33ebea6-5963-4968-882c-4adac5474efb"},} | |
|  | | 3516 | BotulinumToxinAgentsMA08.017g | Pharmacy (08) | MA08.017g | MA08.017 | a4136f55-5f15-4b47-bae8-a1346b70b9aa | Botulinum Toxin Agents | Botulinum Toxin Agents | {"3517": {"Id":3517,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":6216,"PolicyAttachmentPageName":"da943c2f-3c65-4fcb-8a5f-35e5a824dd90"},} | |
|  | | 2971 | BrentuximabVedotin(Adcetris®)MA08.068f | Pharmacy (08) | MA08.068f | MA08.068 | d1c31d6f-4862-453e-89af-54d64ce7abc9 | Brentuximab Vedotin (Adcetris®) | Brentuximab Vedotin (Adcetris®) | {"2972": {"Id":2972,"MPAttachmentLetter":"A","Title":"ICD 10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":5778,"PolicyAttachmentPageName":"893f6d02-ddff-4b9e-b122-6a5fb698f1b0"},} | |
|  | | 3417 | BronchialValvesMA11.020 | Surgery (11) | MA11.020 | MA11.020 | 69c14601-19f4-4a22-869a-ce88af536766 | Bronchial Valves | Bronchial Valves | | |
|  | | 3524 | Burosumab-twza(Crysvita®)MA08.099b | Pharmacy (08) | MA08.099b | MA08.099 | 6fab4e9d-5e32-4f2d-a48f-3b3b7d31608f | Burosumab-twza (Crysvita®) | Burosumab-twza (Crysvita®) | | |
|  | | 3402 | Canakinumab(Ilaris®)MA08.101a | Pharmacy (08) | MA08.101a | MA08.101 | a9edc4ba-8e39-4e75-93f1-eccdd1d9391e | Canakinumab (Ilaris®) | Canakinumab (Ilaris®) | | |
|  | | 3401 | CanesandCrutchesMA05.052b | DME (05) | MA05.052b | MA05.052 | 9ed71d16-85d6-476c-9ed2-2e1a6fb65333 | Canes and Crutches | Canes and Crutches | | |
|  | | 3262 | CapsuleEndoscopyMA07.022d | Medicine (07) | MA07.022d | MA07.022 | d911f4fe-8fe3-42db-a33e-421e8b327cd9 | Capsule Endoscopy | Capsule Endoscopy | | |
|  | | 3059 | CardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)ProgramsMA10.002b | Rehabilitation Services (10) | MA10.002b | MA10.002 | c5973a63-e52f-43d8-a5df-3108449d0314 | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | {"3060": {"Id":3060,"MPAttachmentLetter":"A","Title":"Medically Necessary ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5730,"PolicyAttachmentPageName":"b8ba4853-8872-410a-840c-4a11647197aa"},} | |
|  | | 3423 | CareManagementandCarePlanningServicesMA00.006j | Administrative (00) | MA00.006j | MA00.006 | 8553b5bc-9382-43d1-941c-2ed398ea6963 | Care Management and Care Planning Services | Care Management and Care Planning Services | {} | |
|  | | 3181 | Carfilzomib(Kyprolis™)MA08.062f | Pharmacy (08) | MA08.062f | MA08.062 | baf875dc-3289-463b-afc8-67f64e8ae11a | Carfilzomib (Kyprolis™) | Carfilzomib (Kyprolis™) | | |
|  | | 2236 | CastandSplintApplicationsandAssociatedSuppliesMA00.012c | Administrative (00) | MA00.012c | MA00.012 | 7a7e50a2-46a1-4673-b9d9-59a2fce39403 | Cast and Splint Applications and Associated Supplies | Cast and Splint Applications and Associated Supplies | {"2237": {"Id":2237,"MPAttachmentLetter":"A","Title":"Procedures Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":4985,"PolicyAttachmentPageName":"0a068e16-bb74-4ccb-9a5b-27b1dc464f75"},} | |
|  | | 3274 | CataractSurgeryMA11.054d | Surgery (11) | MA11.054d | MA11.054 | 5095c829-369f-46c3-b691-0adf6863c45b | Cataract Surgery | Cataract Surgery | {"3275": {"Id":3275,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":6073,"PolicyAttachmentPageName":"78c40eb8-686a-4467-8e5c-92a9de5de2b3"},} | |
|  | | 3253 | CatheterAblationofCardiacArrhythmiasMA11.060d | Surgery (11) | MA11.060d | MA11.060 | 9753416e-27fe-43ff-946d-2f4724fb3d68 | Catheter Ablation of Cardiac Arrhythmias | Catheter Ablation of Cardiac Arrhythmias | | |
|  | | 3308 | Cemiplimab-rwlc(Libtayo®)MA08.124a | Pharmacy (08) | MA08.124a | MA08.124 | b20eb9d7-1322-4095-b3fa-f8119ce79e16 | Cemiplimab-rwlc (Libtayo®) | Cemiplimab-rwlc (Libtayo®) | | |
|  | | 3526 | Cerliponasealfa(Brineura®)MA08.089c | Pharmacy (08) | MA08.089c | MA08.089 | af3e4f67-0660-4149-b715-205f07d43919 | Cerliponase alfa (Brineura®) | Cerliponase alfa (Brineura®) | | |
|  | | 3438 | CervicalTractionDevicesforIn-homeUseMA05.009a | DME (05) | MA05.009a | MA05.009 | c98e6881-f694-4a4a-93e0-12285cfbf202 | Cervical Traction Devices for In-home Use | Cervical Traction Devices for In-home Use | | |
|  | | 2912 | Cetuximab(Erbitux®)MA08.031e | Pharmacy (08) | MA08.031e | MA08.031 | c72d3dca-9d0d-4a60-8b91-7b43d611e591 | Cetuximab (Erbitux®) | Cetuximab (Erbitux®) | {"2913": {"Id":2913,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":5413,"PolicyAttachmentPageName":"ed390518-e9c0-4b32-87d2-382240f0324e"},"2914": {"Id":2914,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":5414,"PolicyAttachmentPageName":"1be45d2a-140e-429e-b3a2-32db475c4a2b"},} | |
|  | | 2927 | ChemicalPeelsMA11.103a | Surgery (11) | MA11.103a | MA11.103 | a33f9f91-2a57-415b-85c9-2e9928af5618 | Chemical Peels | Chemical Peels | | |
|  | | 3267 | ChimericAntigenReceptor(CAR)TherapyMA08.093j | Pharmacy (08) | MA08.093j | MA08.093 | 057ee391-bab8-4f1f-b406-27a9810e22e8 | Chimeric Antigen Receptor (CAR) Therapy | Chimeric Antigen Receptor (CAR) Therapy | {"3268": {"Id":3268,"MPAttachmentLetter":"A","Title":"ICD 10 codes","MPPolicyAttachmentInternalSourceId":6114,"PolicyAttachmentPageName":"103b9722-da17-47ee-b650-92fcd0ca61f1"},} | |
|  | | 2960 | ChiropracticServicesMA10.004h | Rehabilitation Services (10) | MA10.004h | MA10.004 | 82fa8d76-e28e-4d03-8e55-485c58416c4e | Chiropractic Services | Chiropractic Services | {"2961": {"Id":2961,"MPAttachmentLetter":"A","Title":"Medically neessary ICD-10 diagnosis codes","MPPolicyAttachmentInternalSourceId":5875,"PolicyAttachmentPageName":"834cf659-9228-46b9-8755-7241a7d8da3f"},} | |
|  | | 1368 | Circulating Tumor Cell (CTC) Assay | Pathology and Laboratory (06) | MA06.030 | MA06.030 | F371FB2E48AFB33885257DBE00723399 | Circulating Tumor Cell (CTC) Assay | Circulating Tumor Cell (CTC) Assay | | |
|  | | 3097 | CoagulationFactorsMA08.004s | Pharmacy (08) | MA08.004s | MA08.004 | eb5f10f4-c8a1-4b10-aba1-7ba53b4e822c | Coagulation Factors | Coagulation Factors | | |
|  | | 3192 | Cobalamin(VitaminB12),FolicAcid,andHomocysteineTestingMA06.032 | Pathology and Laboratory (06) | MA06.032 | MA06.032 | 0e1034a1-44e6-4b1a-ba4a-5f9b439a5a18 | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing | {"3193": {"Id":3193,"MPAttachmentLetter":"A","Title":"ICD 10 CODES FOR MEDICALLY NECESSARY COBALAMIN (VITAMIN B12), FOLIC ACID, AND/OR HOMOCYSTEINE TESTING (CPT CODES 82607, 82746, AND 83090)","MPPolicyAttachmentInternalSourceId":6107,"PolicyAttachmentPageName":"8816a85c-bf20-467e-906a-584a77f59ef8"},} | |
|  | | 2505 | CochlearImplantationMA11.039d | Surgery (11) | MA11.039d | MA11.039 | 2ff992d2-ca4a-42b9-b321-e387ed4804fd | Cochlear Implantation | Cochlear Implantation | | |
|  | | 3437 | Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo™)MA08.128 | Pharmacy (08) | MA08.128 | MA08.128 | c4e07093-c912-4146-8bab-3e038ab4fbce | Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™) | Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™) | | |
|  | | 3383 | CommodeChairsMA05.036b | DME (05) | MA05.036b | MA05.036 | b54c4527-287c-44b4-ba99-2781f6ea0463 | Commode Chairs | Commode Chairs | | |
|  | | 1668 | Complementary and Integrative Health Services | Miscellaneous (12) | MA12.001d | MA12.001 | 85257D39006E7945852585040068A7CD | Complementary and Integrative Health Services | Complementary and Integrative Health Services | | |
|  | | 2752 | CompleteDecongestiveTherapy(CDT)MA07.042 | Medicine (07) | MA07.042 | MA07.042 | af3a51ad-e178-4ab8-87d6-c5f616db4abe | Complete Decongestive Therapy (CDT) | Complete Decongestive Therapy (CDT) | | |
|  | | 2659 | CompositeTissueAllotransplantationoftheHand(s)andFaceMA11.112 | Surgery (11) | MA11.112 | MA11.112 | c751b663-969e-44e9-9ed3-333584162b51 | Composite Tissue Allotransplantation of the Hand(s) and Face | Composite Tissue Allotransplantation of the Hand(s) and Face | | |
|  | | 2637 | CompressionGarmentsMA05.045a | DME (05) | MA05.045a | MA05.045 | ab1071fd-1c46-4266-a71c-6dd8cea5c750 | Compression Garments | Compression Garments | | |
|  | | 2935 | Computer-AidedDetection(CAD)SystemforUsewithChestRadiographsMA09.014a | Radiology (09) | MA09.014a | MA09.014 | 935f4c28-cc58-44c2-a6d0-984f28a62422 | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | Computer-Aided Detection (CAD) System for Use with Chest Radiographs | | |
|  | | 2640 | Computer-AssistedMusculoskeletalSurgicalNavigationalOrthopedicProcedureMA11.088c | Surgery (11) | MA11.088c | MA11.088 | 7eccc322-fc2c-4c32-97f5-d2792e48497b | Computer-Assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | Computer-Assisted Musculoskeletal Surgical Navigational Orthopedic Procedure | | |
|  | | 2041 | ConsultationServicesMA00.049 | Administrative (00) | MA00.049 | MA00.049 | 1a75604c-5542-4601-b256-9e702f9428ba | Consultation Services | Consultation Services | | |
|  | | 2931 | ContinuousGlucoseMonitorsandArtificialPancreasDeviceSystems(APDS)MA00.002h | Administrative (00) | MA00.002h | MA00.002 | 5c1443e6-2913-42a5-8619-005a3242e93b | Continuous Glucose Monitors and Artificial Pancreas Device Systems (APDS) | Continuous Glucose Monitors and Artificial Pancreas Device Systems (APDS) | {"2932": {"Id":2932,"MPAttachmentLetter":"A","Title":"ICD-10: Short term CGM","MPPolicyAttachmentInternalSourceId":5562,"PolicyAttachmentPageName":"113e4f62-516f-4439-b0f6-296f308fbef4"},"2933": {"Id":2933,"MPAttachmentLetter":"B","Title":"THERAPEUTIC LONG-TERM INTERSTITIAL CGMS","MPPolicyAttachmentInternalSourceId":5563,"PolicyAttachmentPageName":"1f15e1a5-4dcb-4ec2-8523-4e24b8cbfa04"},} | |
|  | | 2532 | ContrastAgentsUsedinConjunctionwithEchocardiographyMA09.004c | Radiology (09) | MA09.004c | MA09.004 | 16379ab5-1c4e-4ad3-9aa8-49dea5cd3d30 | Contrast Agents Used in Conjunction with Echocardiography | Contrast Agents Used in Conjunction with Echocardiography | | |
|  | | 3141 | CornealPachymetryUsingUltrasoundMA07.046f | Medicine (07) | MA07.046f | MA07.046 | f646cf51-1c38-4c6d-a854-bbe8c3717e5f | Corneal Pachymetry Using Ultrasound | Corneal Pachymetry Using Ultrasound | {"3142": {"Id":3142,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes Eligible to be Reported for Corneal Pachymetry Using Ultrasound","MPPolicyAttachmentInternalSourceId":5965,"PolicyAttachmentPageName":"2d1de0fa-418e-4379-925d-d0fffd121b24"},} | |
|  | | 2751 | CosmeticProceduresMA12.009a | Miscellaneous (12) | MA12.009a | MA12.009 | 0853e101-4b8c-412e-a9e4-ebc95dc4ec4c | Cosmetic Procedures | Cosmetic Procedures | | |
|  | | 3048 | CoverageofMedicalDevicesMA05.040b | DME (05) | MA05.040b | MA05.040 | 69c3f8a1-1044-489c-869e-7e78dbb55b06 | Coverage of Medical Devices | Coverage of Medical Devices | | |
|  | | 3163 | CranialElectrotherapyStimulationMA05.066a | DME (05) | MA05.066a | MA05.066 | 926424cb-d449-475a-bffd-e766248d6937 | Cranial Electrotherapy Stimulation | Cranial Electrotherapy Stimulation | | |
|  | | 1616 | Criteria for Reimbursement of Emergency Room Services | Administrative (00) | MA00.044b | MA00.044 | 85257D39006E7945852584FD00658A7A | Criteria for Reimbursement of Emergency Room Services | Criteria for Reimbursement of Emergency Room Services | | |
|  | | 3387 | crizanlizumab-tmca(Adakveo®)MA08.109a | Pharmacy (08) | MA08.109a | MA08.109 | 5c85f061-d9b8-458b-977b-a6d0470b0e1f | crizanlizumab-tmca (Adakveo®) | crizanlizumab-tmca (Adakveo®) | | |
|  | | 2645 | CryosurgicalAblationoftheProstateGlandMA11.022a | Surgery (11) | MA11.022a | MA11.022 | f949b8ee-ae93-49e4-af37-675e06be8bd2 | Cryosurgical Ablation of the Prostate Gland | Cryosurgical Ablation of the Prostate Gland | | |
|  | | 2709 | Daratumumab(Darzalex®),Daratumumab,andHyaluronidase-fihj(DarzalexFaspro®)MA08.079i | Pharmacy (08) | MA08.079i | MA08.079 | eeda51c3-f345-4c9c-b1e8-4383e943ae09 | Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®) | Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®) | | |
|  | | 2769 | DayRehabilitationMA10.005b | Rehabilitation Services (10) | MA10.005b | MA10.005 | ebab4b51-cc41-4866-9d3e-f134b810965b | Day Rehabilitation | Day Rehabilitation | | |
|  | | 3009 | DebridementofMycoticandSymptomaticNon-MycoticHypertrophicToeNailsMA11.014g | Surgery (11) | MA11.014g | MA11.014 | b3040a13-2215-4c0c-8fe1-616dc7e9e953 | Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails | Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails | {"3010": {"Id":3010,"MPAttachmentLetter":"E","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (S86.892A - Z79.01), Continued","MPPolicyAttachmentInternalSourceId":5835,"PolicyAttachmentPageName":"59417dc9-2317-41dc-8db6-2bc5830e67e3"},"3011": {"Id":3011,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (A30.0 -E10.21)","MPPolicyAttachmentInternalSourceId":5836,"PolicyAttachmentPageName":"4a4105ce-95c2-4502-a527-62b668faee88"},"3012": {"Id":3012,"MPAttachmentLetter":"D","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (I87.099 - S86.891S), Continued","MPPolicyAttachmentInternalSourceId":5837,"PolicyAttachmentPageName":"4322d6d4-a6f9-4345-966a-49b5ecd7e575"},"3013": {"Id":3013,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E10.22 - E13.3512), Continued","MPPolicyAttachmentInternalSourceId":5838,"PolicyAttachmentPageName":"2fc764b2-4126-4fbb-b1f8-0fa1d9a076c6"},"3014": {"Id":3014,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E13.3513 - I87.093), Continued","MPPolicyAttachmentInternalSourceId":5839,"PolicyAttachmentPageName":"dbe82818-9e73-4df2-ac07-08db634e8392"},} | |
|  | | 3104 | DeepBrainStimulation(DBS)MA11.005d | Surgery (11) | MA11.005d | MA11.005 | 7275a229-55e1-4a18-bca7-047e1f28b32e | Deep Brain Stimulation (DBS) | Deep Brain Stimulation (DBS) | | |
|  | | 3522 | Denosumab(Prolia®,Xgeva®),Romosozumab-aqqg(Evenity®)MA08.052j | Pharmacy (08) | MA08.052j | MA08.052 | 116bf5f6-59fe-4c5b-b271-9a90bf62beb6 | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | {"3523": {"Id":3523,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes","MPPolicyAttachmentInternalSourceId":6189,"PolicyAttachmentPageName":"dd04c740-d70b-48c8-b128-cde0f0c0b1f9"},} | |
|  | | 3271 | DermabrasionforRhinophyma,Septoplasty,Rhinoplasty,andSeptorhinoplastyMA11.099b | Surgery (11) | MA11.099b | MA11.099 | fc1b8cfd-8564-48f4-95e2-35079b441983 | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | | |
|  | | 3346 | DirectAccesstoObstetrics/Gynecology(OB/GYN)ServicesMA00.032d | Administrative (00) | MA00.032d | MA00.032 | 3cc570f5-3a08-4974-a65d-e95d42146963 | Direct Access to Obstetrics/Gynecology (OB/GYN) Services | Direct Access to Obstetrics/Gynecology (OB/GYN) Services | {} | |
|  | | 2651 | Dofetilide(Tikosyn®)UseintheInpatientSettingMA08.021b | Pharmacy (08) | MA08.021b | MA08.021 | fb045038-630a-438d-b076-241198fe9b0c | Dofetilide (Tikosyn®) Use in the Inpatient Setting | Dofetilide (Tikosyn®) Use in the Inpatient Setting | | |
|  | | 3413 | Dostarlimab-gxly(Jemperli)MA08.136c | Pharmacy (08) | MA08.136c | MA08.136 | c37d9c69-6413-4a3b-872a-d26735e8bd34 | Dostarlimab-gxly (Jemperli) | Dostarlimab-gxly (Jemperli) | | |
|  | | 3085 | Drug-ElutingBeadsandBlandEmbolizationfortheTreatmentofHepaticMalignanciesMA07.041b | Medicine (07) | MA07.041b | MA07.041 | ae95d034-1aa3-4388-8961-5b98f504ad3e | Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies | Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies | | |
|  | | 3049 | DurableMedicalEquipment(DME)MA05.044k | DME (05) | MA05.044k | MA05.044 | ddf91086-b3c9-4100-98a0-12059f037016 | Durable Medical Equipment (DME) | Durable Medical Equipment (DME) | {"3050": {"Id":3050,"MPAttachmentLetter":"B","Title":"Items that Do Not Meet the Definition of Durable Medical Equipment (DME) or Excluded from Coverage by Medicare","MPPolicyAttachmentInternalSourceId":5909,"PolicyAttachmentPageName":"fd530b8d-f8b7-430a-a5c0-f1eb2e69d9ae"},"3051": {"Id":3051,"MPAttachmentLetter":"A2","Title":"Equipment that Meets the Definition of Durable Medical Equipment (DME)","MPPolicyAttachmentInternalSourceId":5910,"PolicyAttachmentPageName":"a81e2d1b-7b17-4e0e-b2d7-c11a4124109a"},"3052": {"Id":3052,"MPAttachmentLetter":"A1","Title":"Equipment that Meets the Definition of Durable Medical Equipment (DME)","MPPolicyAttachmentInternalSourceId":5911,"PolicyAttachmentPageName":"0e709ad0-3baa-485b-91f0-7a96554ba026"},} | |
|  | | 2423 | DurableMedicalEquipment(DME)NotSubjecttoaRentaltoPurchaseMaximumMA05.028e | DME (05) | MA05.028e | MA05.028 | 81644841-0f55-4dc1-9476-5ab8d631fd3a | Durable Medical Equipment (DME) Not Subject to a Rental to Purchase Maximum | Durable Medical Equipment (DME) Not Subject to a Rental to Purchase Maximum | | |
|  | | 3306 | Durvalumab(Imfinzi®)MA08.123a | Pharmacy (08) | MA08.123a | MA08.123 | 08bdcc51-41f8-4c2d-a5e2-addbc9e3f053 | Durvalumab (Imfinzi®) | Durvalumab (Imfinzi®) | {"3307": {"Id":3307,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":6037,"PolicyAttachmentPageName":"77def428-a565-43ca-a90c-01e61784580a"},} | |
|  | | 3412 | Eculizumab(Soliris®)andRelatedBiosimilars,Ravulizumab-cwvz(Ultomiris™)MA08.044g | Pharmacy (08) | MA08.044g | MA08.044 | 6d08baf9-f663-4f12-8766-b2e89901736a | Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™) | Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™) | | |
|  | | 2652 | Edaravone(Radicava®)MA08.092a | Pharmacy (08) | MA08.092a | MA08.092 | 3e6b4d1a-b289-45f9-938b-9b8c37e853d4 | Edaravone (Radicava®) | Edaravone (Radicava®) | | |
|  | | 3397 | Efgartigimod-alfa(VyvgartTM)MA08.142 | Pharmacy (08) | MA08.142 | MA08.142 | 546b89d6-0da3-422a-9ab4-74ccbba33c94 | Efgartigimod-alfa (VyvgartTM) | Efgartigimod-alfa (VyvgartTM) | | |
|  | | 2454 | ElectricalContinenceAidMA05.059 | DME (05) | MA05.059 | MA05.059 | d0ed73a0-1d77-4f22-9d58-a33008362521 | Electrical Continence Aid | Electrical Continence Aid | | |
|  | | 3511 | ElectricalStimulationandElectromagneticStimulationfortheTreatmentofWoundsMA07.013d | Medicine (07) | MA07.013d | MA07.013 | 9c10b787-7936-43dc-85af-d1b5f8b51d28 | Electrical Stimulation and Electromagnetic Stimulation for the Treatment of Wounds | Electrical Stimulation and Electromagnetic Stimulation for the Treatment of Wounds | {"3512": {"Id":3512,"MPAttachmentLetter":"A","Title":"ICD-10 Coding","MPPolicyAttachmentInternalSourceId":6285,"PolicyAttachmentPageName":"30a7a7ad-1cae-4a55-857c-5dcd42b5d7e4"},} | |
|  | | 3207 | Electromyography(EMG)Studies:NeedleEMG,SurfaceEMG(SEMG)MA07.050i | Medicine (07) | MA07.050i | MA07.050 | 93ee1465-f44b-4c23-89d8-b92cdb22194c | Electromyography (EMG) Studies: Needle EMG, Surface EMG (SEMG) | Electromyography (EMG) Studies: Needle EMG, Surface EMG (SEMG) | {"3208": {"Id":3208,"MPAttachmentLetter":"G","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5981,"PolicyAttachmentPageName":"49836ea4-38e5-46f7-a25a-2072190d8c41"},"3209": {"Id":3209,"MPAttachmentLetter":"K","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5982,"PolicyAttachmentPageName":"809e3e3d-8606-4246-92c8-b4e01dcf76b8"},"3210": {"Id":3210,"MPAttachmentLetter":"B","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5983,"PolicyAttachmentPageName":"f0cf467b-5e80-4006-a430-2b40f63b291d"},"3211": {"Id":3211,"MPAttachmentLetter":"I","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5984,"PolicyAttachmentPageName":"07fa29ab-8208-4c55-a717-2ccd6436cfc9"},"3212": {"Id":3212,"MPAttachmentLetter":"F","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5985,"PolicyAttachmentPageName":"221edad4-7e51-4955-9586-9fc74211e42d"},"3213": {"Id":3213,"MPAttachmentLetter":"H","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5986,"PolicyAttachmentPageName":"ce65e75a-82ca-45fd-8b4d-3341385e48de"},"3214": {"Id":3214,"MPAttachmentLetter":"C","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5987,"PolicyAttachmentPageName":"c423253c-bef3-43ba-b9cf-795104f6f576"},"3215": {"Id":3215,"MPAttachmentLetter":"A","Title":"Recommended Guidelines for Electrodiagnostic Studies","MPPolicyAttachmentInternalSourceId":5988,"PolicyAttachmentPageName":"3aa8daeb-66f6-447e-a6df-f244feb56a6a"},"3216": {"Id":3216,"MPAttachmentLetter":"J","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5989,"PolicyAttachmentPageName":"28653f86-6f2b-4b4a-9a6c-88f236e5f6d7"},"3217": {"Id":3217,"MPAttachmentLetter":"E","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5990,"PolicyAttachmentPageName":"ad380a2b-0958-46be-8d4c-a4bdc4c66498"},"3218": {"Id":3218,"MPAttachmentLetter":"D","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":5991,"PolicyAttachmentPageName":"a7f7f641-aa18-4b93-8c04-77729b95bc94"},} | |